Menu
  • Join
  • Login
  • Contact
 

Search abstracts


Empagliflozin,improved exercise tolerance and LV functional parameters in rats with CHF in the absence of metabolic disorders.The effect of empagliflozin on LV remodeling requires further study.

  • At: 2017 FIP Congress in Stockholm (Sweden)
  • Type: Poster
  • By: IVKIN, Dmitry (Saint-Petersburg State Chemical-Pharmaceuitical Academy, Center of Experimental Pharmacology, Saint-Petersburg, Russian Federation)
  • Co-author(s): Dmitry Ivkin: Center of Experimental Pharmacology, Saint-Petersburg State Chemical-Pharmaceuitical Academy, Saint-Petersburg, Russian Federation
    Sergey Okovityi: Saint-Petersburg State Chemical-Pharmaceuitical Academy, Saint-Petersburg, Russian Federation
    Marina Krasnova: Center of Experimental Pharmacology, Saint-Petersburg State Chemical-Pharmaceuitical Academy, Saint-Petersburg, Russian Federation
    Andrey Karpov: First Pavlov State Medical University of St. Peterburg, Saint-Petersburg, Russian Federation
  • Abstract:

    Backgrounds

    EMPA-REG OUTCOME trial results shows that empagliflozin significantly decrease the heart failure hospitalization in patients with type 2 diabetes. 

    Aims

    To evaluate in experimental setting the efficacy of empagliflozin, for treatment of chronic heart failure (CHF) in the absence of carbohydrate metabolic disorders.  

    Methods

    CHF was modeled

    ..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses